• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Investors

Investors

Share Info

Financial Info

Documents & Presentations

Company Profile

Advisors

Corporate Governance

2026 Capital Raise

2024 Capital Raise

2023 Capital Raise

Regulatory News Archive

Scancell Holdings PLC is an AIM listed company

Documents & Presentations

5

Regulatory News

5

Corporate Deck

5

Latest News

Result of General Meeting

Oct 20, 2026

Preliminary Results for the year ended 30 April 2026

Oct 9, 2026

View All News

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy